Cargando…

GHR knockdown enhances the sensitivity of HCC cells to sorafenib

Sorafenib is approved for treatment of advanced hepatocellular carcinoma (HCC) by the Drug Administration. However, the efficacy of sorafenib has become very limited because most tumors have developed resistance to this drug. In this study, we found that sorafenib stimulated GHR expression in HCC ce...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gao, Shuang, Ni, Qianwen, Wu, Xiuli, Cao, Tieliu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals 2020
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7585089/ https://www.ncbi.nlm.nih.gov/pubmed/32970612 http://dx.doi.org/10.18632/aging.103625

Ejemplares similares

Chicken GHR natural antisense transcript regulates GHR mRNA in LMH cells
por: Zhang, Li, et al.
Publicado: (2016)

Hsa-miR-4277 Decelerates the Metabolism or Clearance of Sorafenib in HCC Cells and Enhances the Sensitivity of HCC Cells to Sorafenib by Targeting cyp3a4
por: He, Xi, et al.
Publicado: (2021)

LXR activation potentiates sorafenib sensitivity in HCC by activating microRNA-378a transcription
por: Lin, Zhongjie, et al.
Publicado: (2020)

The Enhanced Metastatic Potential of Hepatocellular Carcinoma (HCC) Cells with Sorafenib Resistance
por: Chow, Ariel Ka-Man, et al.
Publicado: (2013)

Removal of growth hormone receptor (GHR) in muscle of male mice replicates some of the health benefits seen in global GHR−/− mice
por: List, Edward O., et al.
Publicado: (2015)

Incapacitated Capicua in Sorafenib-Resistant HCC
por: Yin, Dingzi, et al.
Publicado: (2020)

GHR gene transcript heterogeneity may explain phenotypic variability in GHR pseudoexon (6Ψ) patients
por: Chatterjee, Sumana, et al.
Publicado: (2020)

Dual Targeting of Sorafenib-Resistant HCC-Derived Cancer Stem Cells
por: Shrestha, Ritu, et al.
Publicado: (2021)

Mechanism of sorafenib resistance associated with ferroptosis in HCC
por: Guo, Lingling, et al.
Publicado: (2023)

SAT033 Disruption Of GHR In “Middle Aged” Mice Enhances Insulin Sensitivity And Extends Male Lifespan
por: Duran-Ortiz, Silvana, et al.
Publicado: (2023)

Changing TACTICS in intermediate HCC: TACE plus sorafenib
por: Radu, Pompilia, et al.
Publicado: (2020)

Predictive and Prognostic Factors in HCC Patients Treated with Sorafenib
por: Brunetti, Oronzo, et al.
Publicado: (2019)

Sorafenib and Mesenchymal Stem Cell Therapy: A Promising Approach for Treatment of HCC
por: Hajighasemlou, Saieh, et al.
Publicado: (2020)

Association of GHR Polymorphisms with Milk Production in Buffaloes
por: El-Komy, Shymaa M., et al.
Publicado: (2020)

Hypothalamic GHR—SIRT1 Axis in Fasting
por: de Lima, Juliana Bezerra Medeiros, et al.
Publicado: (2021)

The Exon 3-Deleted Growth Hormone Receptor (d3GHR) Polymorphism—A Favorable Backdoor Mechanism for the GHR Function
por: Falah, Ghadeer, et al.
Publicado: (2023)

Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro
por: Qu, Zhen, et al.
Publicado: (2016)

Systemic Deficiency of GHR in Pigs leads to Hepatic Steatosis via Negative Regulation of AHR Signaling
por: Han, Qi, et al.
Publicado: (2021)

Identification of the cDNA Encoding the Growth Hormone Receptor (GHR) and the Regulation of GHR and IGF-I Gene Expression by Nutritional Status in Reeves’ Turtle (Chinemys reevesii)
por: Zhu, Wenlu, et al.
Publicado: (2020)

Deletion of hepatic growth hormone receptor (GHR) alters the mouse gut microbiota by affecting bile acid metabolism
por: Yu, Zichao, et al.
Publicado: (2023)

eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

Tissue-Specific GHR Knockout Mice: An Updated Review
por: Nagarajan, Akash, et al.
Publicado: (2020)

Tissue-Specific GHR Knockout Mice: Metabolic Phenotypes
por: Sun, Liou Y., et al.
Publicado: (2015)

ARC(GHR) Neurons Regulate Muscle Glucose Uptake
por: de Lima, Juliana Bezerra Medeiros, et al.
Publicado: (2021)

Sorafenib for advanced hepatocellular carcinoma (HCC): impact of rationing in the United Kingdom
por: Palmer, D H, et al.
Publicado: (2013)

Sorafenib in the Treatment of Virus-Related HCC: Differences Between HCV and HBV
por: De Matteis, Serena, et al.
Publicado: (2021)

Divergent evolution in the cytoplasmic domains of PRLR and GHR genes in Artiodactyla
por: Iso-Touru, Terhi, et al.
Publicado: (2009)

Metformin Resensitizes Sorafenib-Resistant HCC Cells Through AMPK-Dependent Autophagy Activation
por: Lai, Hong-Yue, et al.
Publicado: (2021)

Validation of a Lab-on-Chip Assay for Measuring Sorafenib Effectiveness on HCC Cell Proliferation
por: Piccinno, Emanuele, et al.
Publicado: (2021)

Androgen enhances the activity of ETS-1 and promotes the proliferation of HCC cells
por: Ren, Hui, et al.
Publicado: (2017)

Combination of sorafenib and TACE inhibits portal vein invasion for intermediate stage HCC: a single center retrospective controlled study
por: Yao, Qi, et al.
Publicado: (2017)

Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCC patients treated with sorafenib: results from a retrospective analysis of the HCC-AVR group
por: Gardini, Andrea Casadei, et al.
Publicado: (2016)

AG-1024 Sensitizes Sorafenib-Resistant Hepatocellular Carcinoma Cells to Sorafenib via Enhancing G1/S Arrest
por: Zhou, Wei, et al.
Publicado: (2021)

The Mouse CircGHR Regulates Proliferation, Differentiation and Apoptosis of Hepatocytes and Myoblasts
por: Zhang, Weilu, et al.
Publicado: (2023)

NEAT 1 knockdown enhances the sensitivity of human non-small-cell lung cancer cells to anlotinib
por: Gu, Guoqing, et al.
Publicado: (2021)

Combination Therapy of Sorafenib and TACE for Unresectable HCC: A Systematic Review and Meta-Analysis
por: Liu, Lei, et al.
Publicado: (2014)

Elucidating the Molecular Basis of Sorafenib Resistance in HCC: Current Findings and Future Directions
por: Fornari, Francesca, et al.
Publicado: (2021)

Ramucirumab and GSK1838705A Enhance the Inhibitory Effects of Low Concentration Sorafenib and Regorafenib Combination on HCC Cell Growth and Motility
por: D’Alessandro, Rosalba, et al.
Publicado: (2019)

Knockdown of lncRNA TP53TG1 Enhances the Efficacy of Sorafenib in Human Hepatocellular Carcinoma Cells
por: Lu, Qingchun, et al.
Publicado: (2022)

Regulation of the sensitivity of hepatocarcinoma cells by ORMDL3, to sorafenib by autophagy
por: Sun, Yixiao, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_ro1j98m2v33e32j58kjnr1p001